Chance of reimbursement for ADD-ON therapies in Poland and in the world - review of the reimbursement recommendations / Szansa na refundację terapii dodanych w Polsce i na świecie – przegląd rekomendacji refundacyjnych
Journal Title: Przegląd Epidemiologiczny - Year 2018, Vol 72, Issue 1
Abstract
INTRODUCTION: Oncology drugs combined with standard therapies (so-called add-on therapies, e.g. bevacizumab, palbociclib) often receive negative recommendations regarding the legitimacy of public financing, issued by government agencies responsible for their assessment, i.e. health technology assessment agencies. The aim of the study was to estimate the scale of the problem related to the reimbursement of add-on therapies used in the treatment of breast and genitourinary cancers in Poland and in the world. MATERIAL AND METHODS: A multimodal approach was used to select add-on therapies. The reimbursement routes were analysed in 8 reference countries (Poland, Canada, England, Wales, France, Scotland, Australia, New Zealand). Based on a systematic search, data for breast and urogenital cancers were included. RESULTS: A total of 68 reimbursement documents for add-on therapies were identified. The analysis showed that in Poland, 20% of innovative schemes including add-on therapies should be reimbursed, while in the world the percentage of positive recommendations reaches 56%. It was observed that globally (including data for Poland) the chance for a favorable reimbursement recommendation for add-on therapies is 53%, with 29% being positive recommendations with limitations. In Poland, the majority of negative recommendations concern genitourinary cancers in comparison to breast cancer (83% vs 75%). CONCLUSIONS: Poland is at the head of the countries in terms of the number of negative reimbursement recommendations. Bearing in mind the world’s need of modifying the criteria for the evaluation of oncological therapies in the context of the possibility of their reimbursement, one should expect a change in the approach to the assessment of the legitimacy of financing innovative add-on therapies in Poland.
Authors and Affiliations
Ewa Borowiack, Magdalena Marzec, Anna Nowotarska, Joanna Jarosz, Agata Orkisz, Patrycja Prząda-Machno
Keywords
Related Articles
- EP ID EP625372
- DOI -
- Views 57
- Downloads 0
„Health 2020” – new framework for health policy. Part I
The paper presents the new framework for health policy adopted in September 2012 during the 62nd session of World Health Organization (WHO) Regional Committee for Europe as the strategy “Health 2020”. Four priority areas...
Analysis of fatality due to cholera epidemics in Tuliszków parish in 1852
INTRODUCTION. Little is known about the correlation between age, gender-distribution and fatality rate during cholera epidemics. AIM. To analyze the change in the fatality rate with regard to age and gender during choler...
Tetanus in Poland in 2017 / Tężec w Polsce w 2017 roku
In the last decade, the number of tetanus cases in Poland has not exceeded 20 cases. Since 1984, neonatal tetanus has not been reported. OBJECTIVE OF THE WORK. The aim of the study is to present the data of epidemiologic...
Evaluation of human papilloma virus (HPV) vaccination strategies and vaccination coverage in adolescents girls worldwide
STUDY OBJECTIVE. An analysis of HPV vaccination strategies and vaccination coverage in adolescent girls worldwide for the last eight years with regard to potential improvement of vaccination coverage rates in Poland. MET...
Seroprevalence of measles-specific antibodies in the group predominantly afected by measles in 2006-2009 in Poland
INRODUCTION. Irrespective of the high vaccination coverage against measles, sporadic measles outbreaks still occur in Poland. In 2006-2009, a slight increase in the number of measles cases was observed. Of these cases, p...